[go: up one dir, main page]

CY1116166T1 - Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori - Google Patents

Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori

Info

Publication number
CY1116166T1
CY1116166T1 CY20151100014T CY151100014T CY1116166T1 CY 1116166 T1 CY1116166 T1 CY 1116166T1 CY 20151100014 T CY20151100014 T CY 20151100014T CY 151100014 T CY151100014 T CY 151100014T CY 1116166 T1 CY1116166 T1 CY 1116166T1
Authority
CY
Cyprus
Prior art keywords
treatment
new method
pylori infections
pylori
hpg
Prior art date
Application number
CY20151100014T
Other languages
English (en)
Inventor
Markus Gerhard
Christian Schmees
Christian Prinz
Original Assignee
Imevax Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imevax Gmbh filed Critical Imevax Gmbh
Publication of CY1116166T1 publication Critical patent/CY1116166T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02002—Gamma-glutamyltransferase (2.3.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Χρήση υποκατάστατη της γάμμα-γλουταμυλο τρανσπεπτιδάσης του Η. pylori (HPGGT) για την παρασκευή φαρμάκου για την αντιμετώπιση λοιμώξεων από Η. pylori, ιδιαίτερα γαστρο-δωδεκαδακτυλικών διαταραχών, επειδή ο υποκατάστατης αναστέλλει σημαντικά την δραστικότητα της HPGGT και αναιρεί την εξαρτώμενη από την HPGGT καταστολή πολλαπλασιασμού λεμφοκυττάρων όπως εκτιμάται σε δοκιμασία προσδιορισμού πολλαπλασιασμού λεμφοκυττάρων.
CY20151100014T 2006-10-19 2015-01-07 Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori CY1116166T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021936A EP1913955A1 (en) 2006-10-19 2006-10-19 Novel method for treating H.pylori infections
EP07819171.5A EP2081594B1 (en) 2006-10-19 2007-10-19 Novel method for treating h.pylori infections

Publications (1)

Publication Number Publication Date
CY1116166T1 true CY1116166T1 (el) 2017-02-08

Family

ID=37682062

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100014T CY1116166T1 (el) 2006-10-19 2015-01-07 Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
CY20181100811T CY1120487T1 (el) 2006-10-19 2018-08-06 Νεα μεθοδος για τη θεραπεια λοιμωξεων απο ελικοβακτηριδιο του πυλωρου (η. pylori)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181100811T CY1120487T1 (el) 2006-10-19 2018-08-06 Νεα μεθοδος για τη θεραπεια λοιμωξεων απο ελικοβακτηριδιο του πυλωρου (η. pylori)

Country Status (15)

Country Link
US (2) US9090676B2 (el)
EP (3) EP1913955A1 (el)
JP (2) JP5989958B2 (el)
CN (2) CN101594880B (el)
AU (1) AU2007312539A1 (el)
CA (1) CA2666859C (el)
CY (2) CY1116166T1 (el)
DK (2) DK2902038T3 (el)
ES (2) ES2527474T3 (el)
HU (1) HUE039785T2 (el)
LT (1) LT2902038T (el)
PL (2) PL2081594T3 (el)
PT (2) PT2081594E (el)
SI (2) SI2902038T1 (el)
WO (1) WO2008046650A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1913955A1 (en) * 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
JP5904481B2 (ja) * 2011-05-20 2016-04-13 学校法人関西文理総合学園 ピロリ菌の分泌毒素に結合するペプチドおよびその用途
CA2909434A1 (en) * 2013-04-18 2014-10-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inhibiting lymphocyte proliferation in a subject in need thereof
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
CN119954904A (zh) * 2025-01-22 2025-05-09 北京润州生物科技有限公司 一种益生菌的制备方法及其在应用于清除口腔中幽门螺杆菌中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
JP2001504448A (ja) 1996-08-30 2001-04-03 フュルステ，イェンス，ペーター 核酸の鏡面対称選択および進化
WO1998017804A2 (en) * 1996-10-17 1998-04-30 Institut Pasteur A HELICOBACTER ANTIGEN (η-GLUTAMYLTRANSFERASE) AND SEQUENCES ENCODING THE SAME
US20020160456A1 (en) * 1997-06-24 2002-10-31 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
WO2000001825A1 (en) * 1998-07-01 2000-01-13 Institut Pasteur HELICOBACTER ANTIGEN (η-GLUTAMYLTRANSPEPTIDASE) AND SEQUENCES ENCODING THE SAME
JP2000229997A (ja) * 1999-02-10 2000-08-22 Nissui Pharm Co Ltd 環状ペプチド及びエイズワクチン
US6380217B1 (en) * 1999-03-31 2002-04-30 Millennium Pharmaceuticals, Inc. Methods for controlling GGT-positive bacteria
AU5937901A (en) 2000-05-03 2001-11-12 Med Immune Inc Combination therapy of respiratory diseases using antibodies
US20040258699A1 (en) * 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
JP3823268B2 (ja) * 2002-05-30 2006-09-20 独立行政法人科学技術振興機構 ヘリコバクター・ピロリの細胞死誘導剤
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
JP2004307477A (ja) * 2003-03-24 2004-11-04 Kobe University 遺伝子導入型ワクチンの中和抗体誘導能を増強する方法、ワクチンの投与方法
JPWO2005075652A1 (ja) * 2004-02-03 2007-10-11 国立大学法人京都大学 グルタリル−７−アミノセファロスポラン酸（ＧＬ−７−ＡＣＡ）アシラーゼ活性が増強された改変γ−グルタミルトランスペプチダーゼ（改変ＧＧＴ）の製造方法
US20070042448A1 (en) 2005-06-02 2007-02-22 Institute Pasteur Use of enzymes from Helicobacter pylori as therapeutical targets
EP1913955A1 (en) * 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections

Also Published As

Publication number Publication date
PL2081594T3 (pl) 2016-01-29
WO2008046650A1 (en) 2008-04-24
CA2666859C (en) 2016-08-16
HUE039785T2 (hu) 2019-02-28
US9090676B2 (en) 2015-07-28
EP2081594B1 (en) 2014-10-22
PT2081594E (pt) 2015-02-05
JP2015214556A (ja) 2015-12-03
ES2527474T3 (es) 2015-01-26
JP5989958B2 (ja) 2016-09-07
EP1913955A1 (en) 2008-04-23
US20100034846A1 (en) 2010-02-11
EP2902038A1 (en) 2015-08-05
HK1212241A1 (en) 2016-06-10
DK2902038T3 (en) 2018-08-13
EP2081594A1 (en) 2009-07-29
CN101594880A (zh) 2009-12-02
PT2902038T (pt) 2018-10-22
SI2902038T1 (sl) 2018-10-30
EP2902038B1 (en) 2018-06-06
PL2902038T3 (pl) 2018-11-30
CY1120487T1 (el) 2019-07-10
AU2007312539A1 (en) 2008-04-24
CN105879019A (zh) 2016-08-24
JP2010506575A (ja) 2010-03-04
LT2902038T (lt) 2018-09-10
ES2682925T3 (es) 2018-09-24
US20150306201A1 (en) 2015-10-29
CN101594880B (zh) 2016-08-10
US9821048B2 (en) 2017-11-21
SI2081594T1 (sl) 2015-04-30
DK2081594T3 (en) 2015-01-26
CA2666859A1 (en) 2008-04-24
JP6106213B2 (ja) 2017-03-29

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
ATE457301T1 (de) Substituierte aryl-acylthioharnstoffe und verwandte verbindungen, virenreplikationshemmer
CY1111896T1 (el) Απαραβιαστες φαρμακευτικες μορφες δοσολογιας δια του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
ATE448232T1 (de) Substituierte heterozyklen
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
NO20072890L (no) Behandling av mastitt
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
CY1109803T1 (el) Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
EA201000864A1 (ru) Фенилоксетанильные производные